The prospect that hepatitis-C drug sales could soar to $20 billion annually by the end of the decade is spurring attempts by drug companies to assert the patent rights theyll need to grab a piece of the pie. The frenzy has accelerated with the launch of Gilead Sciences Inc.s hepatitis-C treatment, Sovaldi, which racked up an estimated $5 billion in sales in the first half of 2014, in what is believed to be the best-selling prescription drug launch in history.
Posted on: Wed, 23 Jul 2014 07:10:02 +0000
Trending Topics
Recently Viewed Topics
© 2015